{"id":"NCT01963208","sponsor":"Marinus Pharmaceuticals","briefTitle":"Phase 3 Study of Adjunctive Ganaxolone in Adults With Drug-resistant Partial Onset Seizures and Open-label Extension","officialTitle":"A Multicenter, Double Blind, Randomized, Placebo-Controlled Trial to Determine the Efficacy and Safety of Ganaxolone as Adjunctive Therapy for Adults With Drug-Resistant Partial-Onset Seizures Followed by Long-term Open-Label Treatment","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-10","primaryCompletion":"2016-05","completion":"2016-10","firstPosted":"2013-10-16","resultsPosted":"2023-02-14","lastUpdate":"2023-02-14"},"enrollment":405,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Drug Resistant Partial Onset Seizure"],"interventions":[{"type":"DRUG","name":"ganaxolone","otherNames":["gnx"]},{"type":"DRUG","name":"Placebo","otherNames":["pbo"]}],"arms":[{"label":"Double Blind - Cohort 1 - Ganaxolone","type":"EXPERIMENTAL"},{"label":"Double Blind - Cohort 1 - Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Open Label - Ganaxolone in Double-blind phase","type":"EXPERIMENTAL"},{"label":"Double Blind - Cohort 2 - Ganaxolone","type":"EXPERIMENTAL"},{"label":"Double Blind - Cohort 2 - Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Open Label - Placebo in Double-blind phase","type":"EXPERIMENTAL"}],"summary":"The study will evaluate the effectiveness and safety of an investigational drug-ganaxolone - on partial seizure frequency in adults with epilepsy taking a maximum of 3 antiepileptic medications (AEDs).","primaryOutcome":{"measure":"Double Blind: Cohort 2: Percent Change From Baseline in 28-day Seizure Frequency During Titration + Maintenance Period","timeFrame":"Baseline and Week 14","effectByArm":[{"arm":"Double Blind: Cohort 2 - Ganaxolone","deltaMin":-21.28,"sd":null},{"arm":"Double Blind: Cohort 2 - Placebo","deltaMin":-10.25,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.1788"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":24},"locations":{"siteCount":71,"countries":["United States","Australia","Bulgaria","Germany","Poland","Russia"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":24},"commonTop":["Somnolence","Dizziness","Fatigue","Headache","Nasopharyngitis"]}}